

We Claim:

1. A method for the prevention of the loss of visual acuity associated with AMD, which comprises, juxtasclerally administering a pharmaceutically effective amount of the compound anecortave acetate or its corresponding alcohol.

2. The method of Claim 1 wherein the compound is administered as a juxtascleral depot.

3. The method of Claim 2 wherein the depot comprises 3 mg – 30 mg of compound.

4. The method of Claim 3 wherein the depot comprises 15 mg of compound.

5. A method for maintaining visual acuity in a person suffering from AMD, which comprises, juxtasclerally administering a pharmaceutically effective amount of the compound anecortave acetate or its corresponding alcohol.

6. The method of Claim 5 wherein the compound is administered as a juxtascleral depot.

7. The method of Claim 6 wherein the depot comprises 3 mg – 30 mg of compound.

8. The method of Claim 7 wherein the depot comprises 15 mg of compound.

9. A method for the inhibition of lesion growth associated with AMD, which comprises, juxtasclerally administering a pharmaceutically effective amount of the compound anecortave acetate or its corresponding alcohol.

10. The method of Claim 9 wherein the compound is administered as a juxtascleral depot.

11. The method of Claim 10 wherein the depot comprises 3 mg – 30 mg of compound.

12. The method of Claim 11 wherein the depot contains 15 mg of compound.

13. The method of Claim 1, 5, or 9 wherein the compound is administered in a juxtasccleral implant.